434 related articles for article (PubMed ID: 15817912)
41. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
42. Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs.
Chanson P
Neuroendocrinology; 2016; 103(1):50-8. PubMed ID: 25677539
[TBL] [Abstract][Full Text] [Related]
43. Pegvisomant in acromegaly: a multicenter real-life study in Argentina.
Basavilbaso NXG; Ballarino MC; Bruera D; Bruno OD; Chervin AB; Danilowicz K; Fainstein-Day P; Fidalgo SG; Frigeri A; Glerean M; Guelman R; Isaac G; Katz DA; Knoblovits P; Librandi F; Montes ML; Mallea-Gil MS; Manavela M; Mereshian P; Moncet D; Pignatta A; Rogozinsky A; Sago LR; Servidio M; Spezzi M; Stalldecker G; Tkatch J; Vitale NM; Guitelman M
Arch Endocrinol Metab; 2019 Aug; 63(4):320-327. PubMed ID: 31460622
[TBL] [Abstract][Full Text] [Related]
44. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.
Scacchi M; Carzaniga C; Vitale G; Fatti LM; Pecori Giraldi F; Andrioli M; Cattaneo A; Cavagnini F
J Endocrinol Invest; 2011 Oct; 34(9):e291-5. PubMed ID: 21697649
[TBL] [Abstract][Full Text] [Related]
45. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
Ayuk J; Stewart SE; Stewart PM; Sheppard MC
J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
[TBL] [Abstract][Full Text] [Related]
46. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
47. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.
Rubeck KZ; Madsen M; Andreasen CM; Fisker S; Frystyk J; Jørgensen JO
Eur J Endocrinol; 2010 Nov; 163(5):717-26. PubMed ID: 20813787
[TBL] [Abstract][Full Text] [Related]
48. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
49. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Khandji AG; Post KD
Pituitary; 2004; 7(1):21-30. PubMed ID: 15638294
[TBL] [Abstract][Full Text] [Related]
50. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
52. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
53. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
54. Effects of previous growth hormone excess and current medical treatment for acromegaly on cognition.
Brummelman P; Koerts J; Dullaart RP; van den Berg G; Tucha O; Wolffenbuttel BH; van Beek AP
Eur J Clin Invest; 2012 Dec; 42(12):1317-24. PubMed ID: 23083406
[TBL] [Abstract][Full Text] [Related]
55. Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome.
Colao A; Pivonello R; Di Somma C; Tauchmanovà L; Savastano S; Lombardi G
Clin Endocrinol (Oxf); 2007 May; 66(5):714-22. PubMed ID: 17388794
[TBL] [Abstract][Full Text] [Related]
56. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
57. Medical treatment in acromegaly.
Paisley AN; Trainer PJ
Curr Opin Pharmacol; 2003 Dec; 3(6):672-7. PubMed ID: 14644022
[TBL] [Abstract][Full Text] [Related]
58. [Combined therapy of acromegaly with a combination of lanreotide and terguride].
Krsek M; Hána V; Marek J; Justová V; Lacinová Z
Cas Lek Cesk; 2000 Nov; 139(22):690-2. PubMed ID: 11191748
[TBL] [Abstract][Full Text] [Related]
59. Conventional pituitary irradiation is effective in normalising plasma IGF-I in patients with acromegaly.
Gutt B; Hatzack C; Morrison K; Pöllinger B; Schopohl J
Eur J Endocrinol; 2001 Feb; 144(2):109-16. PubMed ID: 11182746
[TBL] [Abstract][Full Text] [Related]
60. Pharmacological approach to the treatment of acromegaly.
Ezzat S
Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
